Ignite Creation Date:
2025-12-25 @ 2:54 AM
Ignite Modification Date:
2026-01-26 @ 2:37 AM
Study NCT ID:
NCT04103333
Status:
COMPLETED
Last Update Posted:
2022-01-28
First Post:
2019-09-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Angelman Syndrome (AS) Biomarker Study
Sponsor:
Biogen
Organization:
Study Overview
Official Title:
A Study to Explore Cerebrospinal Fluid and Blood Biomarkers in Participants With Angelman Syndrome
Status:
COMPLETED
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to measure ubiquitin-protein ligase E3A (UBE3A) protein levels in cerebrospinal fluid (CSF) and to evaluate its utility as a biomarker in support of the development of therapies for AS.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: